• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (151)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Bryan L. Burke, MD; Russell W. Steele, MD; Owen W. Beard, MD; James S. Wood, MD; Thomas D. Cain, MD; Daniel J. Marmer, MS

Arch Intern Med. 1982;142(2):291-293.

Abstract

Skin test reactivity and in vitro lymphocyte stimulation responses to varicella-zoster (VZ) were examined in a large normal population ranging in age from 6 months to 93 years. Waning of cellular immunity, as examined by skin delayed hypersensitivity, began at age 40 years. Skin test responses to phytohemagglutinin, however, remained positive into the eighth decade of life. In vitro lymphocyte stimulation responses to VZ were usually positive (stimulation index 2.5) until age 60 years, after which time levels, as observed with nonimmune individuals, were often demonstrated. Antibody levels, as measured by fluorescent antibody to membrane antigen, remained positive into the ninth and tenth decades of life. This was especially so with a history of reactivation (zoster) VZ infections, while skin test and in vitro responses were rarely positive in those individuals. Thus cellular, as contrasted with humoral, immunity decreases with advancing age, which may account for a propensity to reactivation of VZ virus.

(Arch Intern Med 1982;142:291-293)

Author Affiliations

Footnotes

Reprint requests to University of Arkansas for Medical Sciences, 4301 W Markham, Slot 512, Little Rock, AR 72205 (Dr Steele).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years
Schmader et al.
Clinical Infectious Diseases 2012;0:cir970v1-cir970.
ABSTRACT | FULL TEXT  

Varicella Zoster Disease of the Central Nervous System: Epidemiological, Clinical, and Laboratory Features 10 Years after the Introduction of the Varicella Vaccine
Pahud et al.
The Journal of Infectious Disease 2011;203:316-323.
ABSTRACT | FULL TEXT  

Varicella-Zoster Virus: Another Trigger of Guillain-Barre Syndrome?
Lehmann and Hartung
Clinical Infectious Diseases 2010;51:531-533.
FULL TEXT  

Incidence, Recurrence, and Outcomes of Herpes Simplex Virus Eye Disease in Olmsted County, Minnesota, 1976-2007: The Effect of Oral Antiviral Prophylaxis
Young et al.
Arch Ophthalmol 2010;128:1178-1183.
ABSTRACT | FULL TEXT  

Zoster Vaccine: Current Status and Future Prospects
Oxman
Clinical Infectious Diseases 2010;51:197-213.
ABSTRACT | FULL TEXT  

Influence of Age and Nature of Primary Infection on Varicella-Zoster Virus--Specific Cell-Mediated Immune Responses
Weinberg et al.
The Journal of Infectious Disease 2010;201:1024-1030.
ABSTRACT | FULL TEXT  

Varicella-Zoster Virus-Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine
Weinberg et al.
The Journal of Infectious Disease 2009;200:1068-1077.
ABSTRACT | FULL TEXT  

Herpes Zoster Overview: Natural History and Incidence
Weaver
J Am Osteopath Assoc 2009;109:S2-S6.
ABSTRACT | FULL TEXT  

Varicella-zoster virus reactivation during acute enterovirus infection is associated with CD8 lymphocytopenia
Chia and Chia
BMJ Case Reports 2009;2009:bcr0820080803-bcr0820080803.
ABSTRACT | FULL TEXT  

Double-Blind Study Comparing 2 Dosages of Valacyclovir Hydrochloride for the Treatment of Uncomplicated Herpes Zoster in Immunocompromised Patients 18 Years of Age and Older
Arora et al.
The Journal of Infectious Disease 2008;197:1289-1295.
ABSTRACT | FULL TEXT  

Varicella-Zoster Virus-Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine
Levin et al.
The Journal of Infectious Disease 2008;197:825-835.
ABSTRACT | FULL TEXT  

Vaccination against Herpes Zoster and Postherpetic Neuralgia
Oxman et al.
The Journal of Infectious Disease 2008;197:S228-S236.
ABSTRACT | FULL TEXT  

Prevention of Varicella: Recommendations for Use of Varicella Vaccines in Children, Including a Recommendation for a Routine 2-Dose Varicella Immunization Schedule
Committee on Infectious Diseases
Pediatrics 2007;120:221-231.
ABSTRACT | FULL TEXT  

Herpes Zoster Vaccine: Clinical Trial Evidence and Implications for Medical Practice
Burke
J Am Osteopath Assoc 2007;107:S14-S18.
ABSTRACT | FULL TEXT  

Preventing Varicella-Zoster Disease
Hambleton and Gershon
Clin. Microbiol. Rev. 2005;18:70-80.
ABSTRACT | FULL TEXT  

Case-control study of the effect of mechanical trauma on the risk of herpes zoster
Thomas et al.
BMJ 2004;328:439.
FULL TEXT  

Vaccination to prevent varicella and shingles
Breuer
J. Clin. Pathol. 2001;54:743-747.
ABSTRACT | FULL TEXT  

Racial and Psychosocial Risk Factors for Herpes Zoster in the Elderly
Schmader et al.
The Journal of Infectious Disease 1998;178:S67-S70.
ABSTRACT | FULL TEXT  

Cellular Immunity to Varicella-Zoster Virus in Patients with Major Depression
Irwin et al.
The Journal of Infectious Disease 1998;178:S104-S108.
ABSTRACT | FULL TEXT  

Use of a Live Attenuated Varicella Vaccine to Boost Varicella-Specific Immune Responses in Seropositive People 55 Years of Age and Older: Duration of Booster Effect
Levin et al.
The Journal of Infectious Disease 1998;178:S109-S112.
ABSTRACT | FULL TEXT  

Effect of Hypnotic Suggestion on the Delayed-Type Hypersensitivity Response
Locke et al.
JAMA 1994;272:47-52.
ABSTRACT  

Ocular Varicella-Zoster Virus Infection in the Guinea Pig: A New In Vivo Model
Pavan-Langston and Dunkel
Arch Ophthalmol 1989;107:1068-1072.
ABSTRACT  

Varicella-Zoster Virus Infections: Biology, Natural History, Treatment, and Prevention
STRAUS et al.
ANN INTERN MED 1988;108:221-237.
ABSTRACT